Authors
Cheng, S., Weston, W., Ala, P., Chandler, J. C., Mason, W. J., Vinette, H., Heywood, W. E., Dickman, R., Muntoni, F., Aguti, S., Zhou, H.
Abstract
Efficient and cell type-specific delivery remains a major barrier to the clinical translation of nucleic acid therapeutics (NATs), particularly for fibroblast-driven diseases in which target cells are poorly accessible in vivo. By integrating single-cell transcriptomics with cell-surface protein profiling, we identified platelet-derived growth factor receptor alpha (PDGFR) as a fibroblast-enriched surface receptor. A panel of PDGFA-derived short peptides was designed and screened across multiple human and mouse cell types, leading to the identification of two fibroblast-homing peptides, Pep3 and Pep5, which displayed rapid and preferential uptake in fibroblasts. PDGFR; knockdown reduced peptide internalisation as measured by live-cell imaging, confirming receptor-mediated uptake. To evaluate their potential as delivery vehicles for NATs, a fibroblast-based cellular model of collagen VI-related congenital muscular dystrophy (COL6-CMD) was used for further validation. Lead peptides were conjugated to a splice-switching phosphorodiamidate morpholino oligomer (PMO) targeting the recurrent COL6A1 c.930+189C>T variant. Peptide-PMO conjugates retained exon-skipping activity and Pep3-PMO enhanced collagen VI protein deposition in patient-derived fibroblasts following repeated treatment compared to unconjugated PMO. Transcriptomic profiling demonstrated no activation of inflammatory, oncogenic, or PDGFR; receptor-associated signalling pathways following peptide-PMO treatment. Collectively, these findings establish PDGFR-targeting fibroblast-peptides as a promising platform for selective delivery of NATs to fibroblasts.
Preprint server:
bioRxiv
The authors list and abstract were imported from bioRxiv on 21 Oct 2026.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 15
- Comments 0